Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself
暂无分享,去创建一个
C. Sabin | M. Pepys | P. Hawkins | G. Tennent | A. Zychlinsky | J. Gallimore | D. Graham | J. Gallimore | M. Kahan | J. D. de Diego | P. N. Hawkins | Melvyn C. Kahan | Caroline A. Sabin
[1] C. Sabin,et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[2] J. Giddings,et al. C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[3] P. Reitsma,et al. Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans , 2005, Circulation research.
[4] Lisa M. Schwartz,et al. Distribution of C-reactive protein values in the United States. , 2005, The New England journal of medicine.
[5] J. Tune,et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. , 2005, American journal of physiology. Heart and circulatory physiology.
[6] M. Singer,et al. Inflammation and Endothelial Function: Direct Vascular Effects of Human C-Reactive Protein on Nitric Oxide Bioavailability , 2005, Circulation.
[7] L. Rodríguez-Mañas,et al. Evidence for Sodium Azide as an Artifact Mediating the Modulation of Inducible Nitric Oxide Synthase by C-Reactive Protein , 2005, Journal of cardiovascular pharmacology.
[8] Carmen W van den Berg,et al. Letter regarding article by Li et al, "C-reactive protein upregulates complement-inhibitory factors in endothelial cells.". , 2004, Circulation.
[9] M. D. de Maat,et al. C-reactive protein as a risk factor versus risk marker , 2004, Current opinion in lipidology.
[10] J. Kemp,et al. Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] S. S. Levinson,et al. Poor predictive value of high-sensitivity C-reactive protein indicates need for reassessment. , 2004, Clinical chemistry.
[12] G. Zaloga,et al. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. , 2004, The American journal of medicine.
[13] D. Lang,et al. C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial Preparations , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[14] Prapat Suriyaphol,et al. Possible Protective Role for C-Reactive Protein in Atherogenesis: Complement Activation by Modified Lipoproteins Halts Before Detrimental Terminal Sequence , 2004, Circulation.
[15] S. Akira,et al. Toll-Like Receptors Are Temporally Involved in Host Defense , 2004, The Journal of Immunology.
[16] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[17] Richard D. Weisel,et al. C-Reactive Protein Upregulates Complement-Inhibitory Factors in Endothelial Cells , 2004, Circulation.
[18] K. Kitamura,et al. Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells. , 2004, Biochemical and biophysical research communications.
[19] T. Horio,et al. Secretory production of recombinant human C-reactive protein in Escherichia coli, capable of binding with phosphorylcholine, and its characterization. , 2002, Biochemical and biophysical research communications.
[20] M. Pepys. Pathogenesis, diagnosis and treatment of systemic amyloidosis. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[21] J. Danesh,et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.
[22] G D Lowe,et al. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. , 2000, European heart journal.
[23] M. Pepys,et al. C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction , 1999, The Journal of experimental medicine.
[24] W. Cliff,et al. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. , 1999, Atherosclerosis.
[25] P. Godowski,et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. , 1999, Science.
[26] R Peto,et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.
[27] J. Starr,et al. Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. , 1997, Age and ageing.
[28] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[29] Y. Zhang,et al. Plasma protein insudation as an index of early coronary atherogenesis. , 1993, The American journal of pathology.
[30] M. Pepys,et al. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.
[31] G. Lozanski,et al. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.
[32] S. Poole,et al. Detection of endotoxin in mice by measurement of endotoxin‐induced changes in plasma concentrations of zinc and of the acute‐phase protein serum amyloid P‐component , 1986, The Journal of pharmacy and pharmacology.
[33] A. Rudd,et al. Real-time measurement of serum C-reactive protein in the management of infection in the elderly. , 1986, Age and ageing.
[34] M. Pepys,et al. C‐reactive protein in patients undergoing cardiac surgery , 1986, Anaesthesia.
[35] M. Pepys,et al. Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis. , 1985, Journal of clinical pathology.
[36] S. Poole,et al. Effect of bacterial endotoxin on body temperature, plasma zinc and plasma concentrations of the acute-phase protein serum amyloid p component in mice. , 1984, British journal of experimental pathology.
[37] A. Feinstein,et al. Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins , 1984, The Journal of experimental medicine.
[38] A. Feinstein,et al. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein , 1982, The Journal of experimental medicine.
[39] A. Maseri,et al. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. , 1982, British heart journal.
[40] M. Pepys,et al. Solid phase radioimmunoassays for human C-reactive protein. , 1981, Clinica chimica acta; international journal of clinical chemistry.
[41] M. Pepys. C-REACTIVE PROTEIN FIFTY YEARS ON , 1981, The Lancet.
[42] D. B. Zilversmit,et al. Transfer of Plasma Lipoprotein Components and of Plasma Proteins into Aortas of Cholesterol‐Fed Rabbits , 1981, Arteriosclerosis.
[43] M. Pepys,et al. Complement-independence of the acute-phase production of serum amyloijd P-component (SAP) in mice. , 1980, British journal of experimental pathology.
[44] M. Pepys,et al. Serum amyloid P-component is an acute-phase reactant in the mouse , 1979, Nature.
[45] M. Pepys,et al. Isolation and study of murine C3. , 1977, Immunology.
[46] T. Liu,et al. Primary structure of human C-reactive protein. , 1977, The Journal of biological chemistry.
[47] H. Gewurz,et al. Interactions of C-reactive protein with the complement system. II. C- reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations , 1975, The Journal of experimental medicine.
[48] J. Volanakis,et al. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. , 1974, Journal of immunology.
[49] J. Volanakis,et al. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.
[50] S. Kaufmann,et al. Studying trafficking of intracellular pathogens in antigen- presenting cells , 2002 .
[51] P. Sansonetti,et al. Molecular cellular microbiology , 2002 .
[52] W. Roos,et al. Development of a new microparticle‐enhanced turbidimetric assay for C‐reactive protein with superior features in analytical sensitivity and dynamic range , 1998, Journal of clinical laboratory analysis.
[53] M. Pepys,et al. In vivo turnover studies of C-reactive protein. , 1985, Clinical and experimental immunology.
[54] C. Kindmark,et al. Quantitative determination of individual serum proteins by radio-electroimmuno and use of 125 I-labelled antibodies (application to C-reactive protein). , 1972, Scandinavian journal of clinical and laboratory investigation. Supplementum.